ATN-161 as an Integrin α5β1 Antagonist Depresses Ocular Neovascularization by Promoting New Vascular Endothelial Cell Apoptosis

Background: ATN-161 (Ac-PHSCN-NH2), an antagonist of integrin α5β1, has shown an important influence in inhibiting tumor angiogenesis and metastasis of other tumor types. However, the mechanism of action of ATN-161 and whether it can inhibit ocular neovascularization (NV) are unclear. This study investigated the role of ATN-161 in regulating ocular angiogenesis in mouse models and explored the underlying signaling pathway.

Material/Methods: An oxygen-induced retinopathy (OIR) mouse model and a laser-induced choroidal neovascularization (CNV) mouse model were used to test integrin α5β1 expression and the effect of ATN-161 on ocular NV by immunofluorescence staining, Western blot analysis, and flat-mount analysis. The activation of nuclear factor-κB (NF-κB), matrix metalloproteinase-2/9 (MMP-2/9), and cell apoptosis were detected by immunofluorescence staining, Western blot, real-time RT-PCR, and terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL). The cell proliferation was detected by BrdU labeling.

Results: In OIR and CNV mice, the protein expression level of integrin α5β1 increased compared with that in age-matched controls. The mice given ATN-161 had significantly reduced retinal neovascularization (RNV) and CNV. Blocking integrin α5β1 by ATN-161 strongly inhibited nuclear factor-κB (NF-κB) activation and matrix metalloproteinase-2/9 (MMP-2/9) expression and promoted cell apoptosis, but the effect of ATN-161 on proliferation in CNV mice was indirect and required the inhibition of neovascularization. Inhibiting NF-κB activation by ammonium pyrrolidinedithiocarbamate (PDTC) reduced RNV and promoted cell apoptosis in ocular NV.

Conclusions: Blocking integrin α5β1 by ATN-161 reduced ocular NV by inhibiting MMP-2/MMP-9 expression and promoting the cell apoptosis of ocular NV.

MeSH Keywords: Apoptosis • Integrin alpha5beta1 • Matrix Metalloproteinases • Neovascularization, Pathologic • NF-kappa B

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/907446
Background

Angiogenesis plays a crucial role in physiological and pathological processes such as collateral vessel formation, normal wound repair, arthritis, tumor growth, ischemic retinopathies, and choroidal neovascularization (CNV) [1,2]. The disruption of the balance between anti-angiogenic and pro-angiogenic factors leads to pathological neovascularization (NV). So far, several target molecules related to angiogenesis have been studied and vascular endothelial growth factor (VEGF) was deemed to play a significant role in ocular NV diseases. Anti-VEGF treatment was used to inhibit ocular NV and tumor NV. However, this treatment is effective in only some patients with ocular NV [3,4], and problems such as ocular inflammation [5–7], cardiovascular toxicities [7], ocular hemorrhage, and stroke [8] still need to be resolved. Therefore, potential therapeutic targets in addition to VEGF need to be developed [9].

Integrins are a family of enzymatically inactive cell adhesion receptors, including 19 different α subunits and 8 different β subunits, forming at least 25 different integrins with distinct ligand-binding specificities [10]. Integrin α5β1, as a member of the integrin family, plays a significant role in both cell-cell and cell-extracellular matrix interactions. It also modulates cell adhesion, migration, differentiation, and angiogenesis [10–12]. Integrin α5β1 is a specific receptor of fibronectin and is upregulated in growth factor-induced NV [11,13], whereas the expression of integrin α5β1 is low in quiescent vascular cells [13,14].

ATN-161 is an antagonist of integrin α5β1 derived from the synergy domain (PHSRN) of human fibronectin, in which a cysteine residue takes over from an arginine in the primeval sequence (PHSCN) [15]. Some studies indicated that ATN-161 inhibited tumor growth, metastasis, and extended survival in several tumor models, both as a single agent and in combination with radiochemotherapy [16–18]. Although the importance of ATN-161 in inhibiting tumor angiogenesis and metastasis of other tumor types has been described previously, its mechanism of action and whether ATN-161 inhibits ocular NV is not clear. Therefore, this study investigated the influence of ATN-161 in regulating ocular angiogenesis in mouse models and explored the underlying signaling pathway.

Material and Methods

Animal care and ethics statement

All the mice included in this study were specific pathogen-free and were based on C57BL/6 mice (Charles River, Wilmington, MA). Animal care and all procedures were carried out in accordance with the Health Guide for Care and Use of Laboratory Animals (National Institutes) and were approved by the Scientific Investigation Board (approval no. SYXK-2003-0026) of Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Mouse model of oxygen-induced retinal neovascularization (RNV) and flat-mount analysis

Seven-day-old C57BL/6 mice were exposed to oxygen (75±3%) for 5 days along with their wet nurse, and were returned to room air at postnatal day 12 (P12), as previously described [19]. At P12, these C57BL/6 mice were randomly divided into groups. Both eyes received an intravitreal injection of 1 μL of 0.1 μg/μL, 1.0 μg/μL, and 10 μg/μL ATN-161 or 1 μL of PBS. Pulled glass micropipettes, the Harvard Pump Microinjection System, and a dissecting microscope were used in the course of intraocular injection, as previously described [1]. At P18, the eyes were harvested and fixed in 4% paraformaldehyde solution for at least 4 h at room temperature. Retinas were carefully dissected and incubated with fluorescein isothiocyanate (FITC)-Griffonia simplicifolia Lectin-B4 (Vector Laboratories, Inc., CA, USA) for 40 min in the absence of light [4]. After that, the retinas were mounted in fluorescence mounting medium (Dako, Glostrup, Denmark) on glass slides. Retinal flat-mount images were captured under a fluorescence microscope (Nikon, New York, NY) and analyzed using Image-Pro Plus software (Media Cybernetics, Silver Spring, MD, USA).

Mouse model of CNV and flat-mount analysis

CNV was stimulated through laser-induced Bruch’s membrane rupture, as described previously [20]. In brief, the pupils from 6- to 8-week-old female mice (C57BL/6) were diluted with 1% tropicamide after being anesthetized with ketamine hydrochloride. Using an OcuLight GL diode laser (Iridex, CA, USA), the laser spots with a bubble without hemorrhage, indicating disrupted Bruch’s membranes, were produced, confirmed effective, and then included in the study. The laser parameters were: spot size 100 μm, 0.1 s duration, and 120 mW. At days 0 (D0) and 7 (D7) after laser treatment, the mice were administered PBS (1 μL) in one eye and ATN-161 (1 μL, 1.0 μg/μL) in the other eye. At day 14 (D14), the choroidal membranes of the mice were carefully dissected and flat-mounted after perfusion with 50 mg/mL of fluorescein-labeled dextran (Sigma-Aldrich, MO, USA) from the left ventricle [21], and then photographed using a fluorescence microscope (Nikon, New York, NY). The total area of CNV at each rupture site was assessed using Image-Pro Plus software [21].

Immunofluorescence staining

We prepared 10-μm-thick slices from eyes of OIR mice, CNV mice, and age-matched controls, fixed them with 4% paraformaldehyde at room temperature, and then permeabilized with 0.1% Triton X-100 in PBS, and then blocked with 1% BSA in PBS. Primary antibodies against CD31 and VEGF were used to stain retinal vessels and VEGF in CNV respectively. Positive signals were visualized with Alexa Fluor 568 secondary antibodies (Invitrogen). Finally, images were captured using a confocal microscope (Leica, Wetzlar, Germany).
them in 0.5% Triton-X-100. After blocking in 5% bovine serum albumin, these slices were incubated with integrin α5, integrin β1 (Santa Cruz Biotechnology), IxBα, phosphorylated-IxBα (Abcam), p65, and phosphorylated (ser311) p65 (Cell Signaling Technology) primary antibodies overnight, and then incubated in the mixture of FITC-secondary antibodies (Cell Signaling Technology) and Dylight 594 Griffonia simplicifolia Lectin-B4 (Vector Laboratories, Inc., CA, USA). Prolong gold antifade reagent with 4', 6-diamidino-2-phenylindole (DAPI) (Invitrogen) was used to incubate the slices before the images of sections were examined and acquired by fluorescence microscopy.

Western blotting

Proteins of retinas harvested from OIR mice at P15 or P18, posterior segments (retina/choroid complex) from CNV mice at D3 or D14, and age-matched controls were extracted using a protein extraction kit (Beyotime, Shanghai, China). Protein concentrations were measured by use of a Bicinchoninic Acid Protein Quantification Assay Kit (Thermo-Fisher Scientific, Göteborg, Sweden). The samples were adjusted into 40-µg protein content and mixed with a suitable volume of 5× sodium dodecyl sulfate (SDS)-sample buffer (Thermo-Fisher Scientific), separated in proper SDS gel, and transferred onto polyvinylidene fluoride membranes (Millipore, Bedford, MA, USA). We used 5% nonfat dried milk in Tris-buffered saline (TBS) with Tween 20 (20mM Tris, 100mM NaCl, Ph 7.6, 0.1% Tween 20) to block these membranes. After incubation with primary antibodies overnight at 4ºC, membranes were incubated with secondary antibodies conjugated with horseradish peroxidase (Cell Signaling Technology) for 2 h at room temperature. Primary antibodies included integrin α5, integrin β1, p65, phosphorylated (ser311) p65, cleaved-poly-ADP-ribose polymerase (PARP), β-actin (Cell Signaling Technology), IxBα, phosphorylated IxBα, matrix metalloproteinase-2 (MMP-2), MMP-9 (Abcam), and cleaved caspase-3 (Millipore). Western blotting detection solutions (enhanced chemiluminescence, Millipore) were used to visualize immunoreactive bands, and image J software (National Institutes of Health, MD, USA) was used to measure mean band intensities.

Quantitative reverse transcription polymerase chain reaction (RT-PCR)

Total RNA of retinas from OIR mice and age-matched controls was isolated, and 2 µg of RNA of each sample was reverse-transcribed into complementary DNA (cDNA) using a cDNA synthesis kit (Roche, Basel, Switzerland). RT-PCR was carried out using SYBR Green Mix (Roche, Basel, Switzerland) in a 20 µL volume on the ABI 7500 Real-time PCR system (Applied Biosystems, CA, USA). Housekeeping gene cyclophilin A was used to normalize relative expression of target genes. The relative quantification of different groups was calculated by 2^-ΔΔCT method. All PCR primers were as follows:

- IxBα, 5'-AGGACGGAGTACGAGCACA-3' (sense), 5'-CGTGGATGTTGCAATGC-3' (antisense);
- p65, 5'-GCGTACACATTCTGGGGAGT-3' (sense), 5'-ACCGAACGGAGCTATC-3' (antisense) [22];
- MMP-2, 5'-GCTGCTTCCTCTGCTGATTA-3' (sense), 5'-GTTACGTCAGCACCTTCTTT-3' (antisense) [21];
- MMP-9, 5'-TGCACGTGGCTTGATTCTTG-3' (sense), 5'-TGCCGCTTATGTCGTCTTATTC-3' (antisense) [21];
- Cyclophilin A, 5'-CAGACGCCAAGGTGGCTATT-3' (sense), 5'-TGCTTTGGAACATTGTTGCA-3' (antisense) [4].

Terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL)

A mouse model of CNV was established as described earlier. At D0 and D7 after photocoagulation, the mice were given ATN-161 (1 µL, 1 µg/µL) or PDTC (1 µL, 10μM) in one eye and PBS (1 µL) in the other eye. At D14, their eyes were frozen in Tissue-Tek OCT media (Sakura Finetek), and then 10-µm-thick slices were harvested. We used 4% paraformaldehyde to fix tissue sections and permeabilization solution (freshly prepared, 0.1% Trion X-100 in 0.1% sodium citrate) was used to permeabilize the plasma membrane of cells. These sections were then incubated with a terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) reaction mixture (Roche, Basel, Switzerland) at 37ºC for 60 min, Dylight 594 Griffonia simplicifolia Lectin-B4 (Vector Laboratories) for 40 min at room temperature, and 4', 6-diamidino-2-phenylindole (DAPI) (Beyotime Biotechnology) for 5 min at room temperature, and then washed for 30 min in PBS. All these procedures were performed in the dark and the surroundings of the samples were kept dry. After mounting the sections with mounting medium (Dako), we used a fluorescence microscope to examine the images.

BrdU labeling and immunofluorescence staining

Proliferation of vascular endothelial cells in CNV mice was assessed by immunofluorescence staining for 5-bromo-2-deoxyuridine (BrdU). At D0 and D7 after photocoagulation, the mice were given an intravitreal injection with ATN-161 (1 µL, 1 µg/µL) or PDTC (1 µL, 10μM) in one eye and BrdU (Sigma, St. Louis, MO) 0.2 mg per gram body weight at D2, D5, D7, D10, D13, and D14 [23,24]. Eyes were collected at D7 and D14 and fixed with 4% paraformaldehyde for 1 h and then cut into 10-µm-thick slices. After being washed and permeabilized in PBS-T (PBS containing 1% Triton X-100) for 30 min, these slices were placed in 2N HCl for 30 min at room temperature and then washed 3 times with PBS-T. Before incubated in the mixture of Alexa 488-conjugated anti-rat secondary antibody (Abcam) and Dylight 594 Griffonia simplicifolia Lectin-B4 (Vector Laboratories), the slices were incubated in BrdU primary antibody (Abcam) overnight at 4ºC. Prolong gold antifade reagent
with DAPI (Invitrogen) was used to label nuclei. The choroidal membranes of the mice were carefully dissected and flat-mounted after performing the steps described above. The images were captured by fluorescence microscopy (Nikon).

**Figure 1.** Expression level of integrin α5β1 in OIR and CNV mice. (A) Immunofluorescent staining of integrin α5β1 and Dylight 594 Griffonia simplicifolia Lectin-B4 (a marker for VEC) in OIR, CNV, and age-matched control mice. Arrowheads point to positive areas. (B, C) Western blot analysis was used to evaluate integrin α5 and integrin β1 expression at P15 in OIR mice on day 3 after photocoagulation in CNV mice and age-matched controls. Relative protein expression of integrin α5 and integrin β1 normalized to β-actin. Data are expressed as the mean ±SEM from 3 independent experiments. Data were analyzed using the t test. * P<0.05, ** P<0.01, *** P<0.001.

**Statistical analysis**

All data are presented as mean values ± standard error of the mean (SEM). The two-tailed t test was adopted to analyze the differences between 2 groups. The Student-Newman-Keuls method was used to analyze the multiple comparisons. All statistical analyses were performed using SAS 9.0 software (SAS...
Institute Inc., Cary, NC, USA). P<0.05 was considered to be statistically significant.

**Results**

**Expression of integrin α5β1 was increased in retinas of OIR mice and retina/choroid complex of CNV mice**

Integrin α5β1 expression in different mouse models (OIR and CNV) was investigated by immunofluorescence staining and Western blot. The protein levels of integrin α5 and β1 increased significantly in P15 retinas with OIR and D3 retina/choroid complex with CNV compared with age-matched controls (Figure 1B, 1C). The results of immunofluorescence staining showed that integrin α5 and β1 expression levels in OIR and CNV mice were even higher, and the merged images showed that integrin α5 and β1 were co-located with vascular endothelial cells (VECs) (Figure 1A). These findings suggest that integrin α5β1 participates in NV progression.

**ATN-161 inhibited the expression of integrin α5β1 in retinas of the OIR mice**

To investigate the effects and effective concentration of ATN-161, assays were performed in the mouse model of OIR. Western blot assay (Figure 2) demonstrated that ATN-161 significantly inhibited the expression of integrin α5β1 at the concentrations of 1.0 μg/μL and 10 μg/μL compared with PBS-injected eyes.

**Intravitreous injection of ATN-161 suppressed the growth of RNV and CNV**

The mouse model of OIR was established as described above. Compared with the eyes treated with PBS (Figure 3A), the RNV areas were significantly reduced in eyes treated with 0.1 μg/μL (Figure 3B), 1.0 μg/μL (Figure 3C), and 10 μg/μL (Figure 3D) of ATN-161 (P<0.05), which were not significantly different from each other (P>0.05, Student-Newman-Keuls, Figure 3E). These findings demonstrate that ATN-161 inhibited RNV in the mouse model of OIR. Based on the results from Figure 2...
and Figure 3A–3E, 1.0 μg/μL was used as an optimal dosage to test the influence of ATN-161 on the CNV model. The choroidal flat mounts indicated that the areas of NV treated with ATN-161 (Figure 3G) were significantly smaller compared with the regions treated with PBS (Figure 3F).

**Inhibition of integrin α1β1 by ATN-161 reduced NF-κB activation and expression of MMP-2/MMP-9 in OIR mice**

The OIR mice were injected intravitreously with different concentrations of ATN-161 (0.1 μg/μL, 1.0 μg/μL, and 10 μg/μL) in one eye and PBS in the other eye at P12. Immunofluorescence
Figure 4. Inhibition of integrin α5β1 reduced NF-κB activation and MMP-2/MMP-9 expression in OIR mice. OIR mice were injected intravitreally with 1 μL of PBS or ATN-161 (0.1 μg/μL, 1.0 μg/μL, and 10 μg/μL) at P12. (A) Immunofluorescent staining of phosphorylated IkBα (p-IκBα), total IkBα, phosphorylated p65 (p-p65), total p65, and lectin (red) in OIR mice treated with ATN-161 (1.0 μg/μL) or PBS. The arrowheads indicate the positive regions for each labeling staining. (B) The retinal proteins of P15 mice were tested by Western blot assays for p-IκBα, total IκBα, p-p65, total p65, MMP-2, MMP-9, and β-actin. (C–F) Quantitative assessment of data in B (n=3). Three independent assays were performed, and data are shown as the mean ±SEM. * P<0.05, ** P<0.01. (G–J) OIR mice were injected intravitreally with 1 μL of PBS or 1 μL of ATN-161 (1.0 μg/μL) at P12; the retinal mRNA expression levels of IkBα (G, n=6), p65 (H, n=6), MMP-2 (I, n=6), and MMP-9 (J, n=7) at P15 were tested by RT-PCR. The 2−ΔΔCT method was used and cyclophilin A was used as endogenous normalization. Statistical analysis was carried out using the t test. Data are expressed as the mean ±SEM.
Figure 5. Inhibition of activation of NF-κB through PDTC reduced RNV in OIR mice. (A) At P12, OIR mice were intravitreously injected with 1 μL of PBS or PDTC (1 μM, 10 μM, 100 μM, 1 mM, and 10 mM). At P15, the retinal total proteins were isolated and determined by Western blot assays for p-IκBα, total IκBα, and β-actin. (B) Data in A are shown as mean ±SEM. Student-Newman-Keuls was used for statistical analysis (**P < 0.01). (C) Whole retinas were stained with FITC-lectin and flat-mounted at P18 (C-a: OIR, n=14; C-b: PBS, n=14; C-c: 1 μM, n=14; C-d: 10 μM, n=14; C-e: 100 μM, n=14; C-f: 1 mM, n=14; C-g: 10 mM, n=14). Statistical analysis was performed using the t test (C-h) * P<0.05.
staining in OIR mice at P18 showed that p-IκBα, IκBα, p-p65, and p65 were mostly co-located with RNV and the increased expression of p-IκBα, IκBα, p-p65, and p65 in OIR mice treated with PBS was significantly inhibited in the OIR mice treated with ATN-161 (Figure 4A). The results revealed that ATN-161 inhibited the activation of NF-κB at concentrations of 10 μM, 100 μM, 1 mM, and 10 mM. The OIR mice injected intravitreally with PDTC in the eyes appeared to have less RNV compared with the fellow eyes treated with PBS as control (Figure 5C).

**ATN-161 and PDTC promoted endothelial cell apoptosis of RNV and CNV**

The mice with CNV or OIR were injected intravitreally with 1 μL ATN-161 (1 μg/μL) or PDTC (10 μM) in one eye and 1 μL of PBS in the other eye at D0 and D7 (CNV mice) or P12 (OIR mice). The eyes from CNV mice at D14 after photocoagulation and OIR mice at P18 were prepared for TUNEL and Western blot analysis. Observation under a fluorescence microscope revealed that the eyes injected intravitreally with ATN-161 or PDTC had less NV and more TUNEL-positive cells compared with controls in both models (Figure 6). The Western blot assays showed

Inhibition of NF-κB activation by PDTC reduced RNV in OIR mice

The OIR mice received intravitreal injections of different concentrations of PDTC in one eye and PBS in the contralateral eye at P12. Western blot analysis (Figure 5A) was used to evaluate p-IκBα and IκBα protein expression at P15. The analysis of results revealed that PDTC significantly reduced the activation of NF-κB (Figure 5B) at concentrations of 10 μM, 100 μM, 1 mM, and 10 mM. The OIR mice injected intravitreally with PDTC in the eyes appeared to have less RNV compared with the fellow eyes treated with PBS as control (Figure 5C).
that ATN-161 and PDTC promoted the cleavage of caspase-3 and PARP (Figure 7). All of these data show that ATN-161 promoted endothelial cell apoptosis of RNV and CNV.

**Effect of ATN-161 on CNV and cell proliferation in vivo**

To assess the effect of ATN-161 to vascular cell proliferation in vivo, we evaluated the BrdU labeling in CNV mice at D7 and D14. The immunofluorescence staining analysis of CNV mice treated with PBS or ATN-161 (1 μg/μL) showed that CNV- and BrdU-positive cells significantly decreased following treatments with ATN-161, while the ratio of BrdU- and CD31-positive cells (BrdU/CD31) was not significantly different between the 2 groups (PBS group and ATN-161 group) (Figure 8).

All these results indicate that the effects of ATN-161 on proliferation in CNV mice were indirect and needed the inhibition of neovascularization.

**Discussion**

The aim of our study was to determine the influence of ATN-161 in ocular NV and to explore the underlying mechanisms. The roles of integrin α5β1 in angiogenesis have been well studied in tumor research. Research showed that integrin α5β1 was upregulated in tumor angiogenesis, but not in normal vasculature [13]. In early atherogenesis, integrin α5β1 signaling critically regulated oxLDL-induced pro-inflammatory responses [25].
Figure 8. Effect of ATN-161 on NV and cell proliferation in CNV mice. The CNV mice were labeled with BrdU at D2, D5, D7, D10, D13, and D14 by intraperitoneal injection and treated with ATN-161 (1.0 μg/μL) or PBS at D0 and D7 by intravitreous injection. (A) Immunofluorescent staining of lectin and BrdU from CNV mice treated with ATN-161 (1.0 μg/μL) or PBS. (B) Immunofluorescent images of flat-mounted choroids from CNV mice at D7 and D14. The arrowheads indicate the positive regions for each labeling staining. (C) CNV, BrdU-positive cells, and BrdU/CD31 (the ratio)-positive cells analysis of CNV mice at D7 (PBS group, n=11; ATN-161 group, n=15), D14 (PBS group, n=15; ATN-161 group, n=16). Data were expressed as mean ±SEM and were analyzed using the t test. *** P<0.001.
Some research demonstrated that although ATN-161 could interact with multiple integrin β subunits, it has only been shown to inhibit α5β1 integrin signaling [25]. A phase 1 clinical trial showed an excellent safety profile for the use of ATN-161 in patients with advanced solid tumors [26]. ATN-161 could also be redirected for use in atherosclerosis [25]. Similar results were obtained with ATN-161 in assays using the models of colon and prostate cancer, which showed antitumor activity as well as the ability to inhibit soft tissue metastasis [17,18]. However, few studies investigated ocular NV. Some research showed that in activated ARPE-19 cells and proliferative vitreoretinopathy membranes, the expression of integrin α5β1 was higher compared with that in the control eyes [27]. In our present study, 2 mouse models of ocular NV were used to investigate the potential role and underlying mechanism of action of ATN-161. The protein levels of integrin α5β1 increased in the CNV and OIR mice, indicating a close relationship between integrin α5β1 and ocular NV. Next, we explored the inhibition of integrin α5β1 by ATN-161 and demonstrated that ATN-161 inhibited the protein expression of integrin α5β1 in a dose-dependent manner. This was similar to the findings of a recent study, which showed that the VEGF-mediated increase in integrin α5β expression was inhibited by ATN-161 [28]. The NV areas were reduced in OIR and CNV mice after treatment with ATN-161 compared with PBS groups. These results further support the important role of integrin α5β1 in NV and extend the findings of a previous study demonstrating that integrin α5β1 is expressed in 2 eyes with proliferative vitreoretinopathy (PVR) [29] but was not expressed in the normal retinal pigment epithelium cell layer [30]. These results are in accordance with a recent study showing that integrin α5β1 participates in the development and progression of CNV and ATN-161 inhibited laser-induced CNV [28].

The process of angiogenesis is complicated and involves extracellular matrix proteolysis, endothelial cells proliferation and migration, and synthesis of the new matrix in the destination [31]. Because of their ability to degrade basal membrane and extracellular matrix proteins, MMP family proteins play significant roles in angiogenesis. More and more studies demonstrate that MMP-2 and MMP-9 are released at the site of inflammation to regulate angiogenesis [32] and contribute significantly to the development of diabetic retinopathy (DR) [33–35]. In our study, MMP-2 and MMP-9 expression increased in the OIR mice compared with the control mice. When treated with ATN-161, the MMP-2 and MMP-9 mRNA and protein expression of OIR mice significantly decreased. These data suggest that ATN-161 reduces ocular NV by inhibiting MMP-2 and MMP-9 expression.

NF-κB is normally sequestered by IκB in the cytoplasm. IκB phosphorylation results in ubiquitin-dependent protein degradation, and subsequently releases IκB-bound NF-κB from the cytoplasm. The entry of NF-κB to nuclei activates transcription of many cytokines, chemokines, and growth factor genes [36]. NF-κB is an important therapeutic target in several chronic inflammatory diseases, enabling conspicuous downregulation of macrophage-produced pro-inflammatory cytokines [37–39]. In cancer, NF-κB activation has been correlated with cell proliferation, survival, invasion, and angiogenesis, making it a potentially desirable target for therapy. Agents that inhibit NF-κB have been shown to reduce tumor growth and induce apoptosis in malignant cells [40]. Nuclear localization of NF-κB is associated with breast cancer and may be associated with the escape of these tumor cells from apoptosis [41]. This phenomenon was also observed in cell models [42,43]. All of these results indicate that activation of NF-κB inhibits apoptosis. In our study, the activation of NF-κB signaling was increased in OIR mice compared with normal control mice. PDTC was used to block NF-κB signal activation, and the area of RNV was estimated through flat-mount analysis in the OIR mice treated with PDTC. The assays showed that the area of RNV in the PDTC group was decreased compared with the OIR mice treated with PBS. To further validate the underlying mechanism in vivo, assays were performed with different concentrations of ATN-161 to detect the activation of p-IκBα and p-p65 in the OIR mouse model. The results indicated that ATN-161 decreased the activation of NF-κB in the OIR mice. The CNV and OIR mice treated with ATN-161 were used to detect the protein levels of cleaved caspase-3 and PARP by Western blot and cell apoptosis by TUNEL. The results indicated that blocking the expression of integrin α5β1 by ATN-161 or the activation of NF-κB by PDTC induced the cleavage of caspase-3 and PARP, and led to apoptosis.

Reduced neovascularization could be a result of either apoptosis or suspended proliferation, or both. To determine if ATN-161 affects vascular cell proliferation aside from apoptosis, we evaluated the effect of ATN-161 on cell proliferation by BrdU labeling in the CNV mouse model. In previous studies, the expression of integrin α5β1 increased in response to angiogenic factors [28,44] and the interaction between fibronectin and integrin α5β1 has been found to promote cell proliferation in human RPE [27,45], human choroidal endothelial cells (hCECs) [28], and vascular endothelial cells [46]. However, ATN-161 did not attenuate the VEGF-induced proliferation of hCECs at any concentration [28]. Another study of serum-driven MDA-MB-231 cell has shown that ATN-161 did not seem to inhibit cell proliferation in vitro. It has been reported that the lack of an anti-proliferative effect of ATN-161 on MDA-MB-231 cells in vitro could be explained by low copy numbers of integrin α5β1 and αvβ3, an alternate receptor for ATN-161, or the insufficient simultaneous inhibition of MAPK and FAK signaling [16,47]. In contrast, ATN-161 had a significant influence on the proliferation of MDA-MB-231 tumors in vivo, indicating that the effects of ATN-161 on proliferation in vivo were indirect and required the inhibition of angiogenesis [16]. In our study, the...
immunofluorescence staining analysis of CNV mice showed that CNV- and BrdU-positive cells significantly decreased following treatments with ATN-161, while the ratio of BrdU- and CD31-positive cells (BrdU/CD31) was not significantly different between the 2 groups (PBS group and ATN-161 group). Our results are consistent with previous research, indicating that reduced neovascularization is a result of promoting apoptosis, not the cause of directly suspended proliferation in vivo.

Conclusions

The main findings of our study are: (1) blocking integrin α5β1 through ATN-161 can inhibit ocular NV, suggesting that ATN-161 is a potential treatment for ocular diseases associated with angiogenesis; and (2) Blocking integrin α5β1 strongly inhibited expression of MMP-2/MMP-9 and promoted cell apoptosis of ocular NV. These results suggest a novel therapy for angiogenesis-related ocular diseases aside from anti-VEGF therapy.

Acknowledgment

The authors are grateful for facility and field assistance from the Shanghai Institute of Burns.

Conflict of Interest

None.
35. Mohammad G, Siddiquei MM: Role of matrix metalloproteinase-2 and -9 in the development of diabetic retinopathy. J Ocul Biol Dis Inf, 2012; 5: 1–8
36. Häcker H, Karin M: Regulation and function of IKK and IKK-related kinases. Sci STKE, 2006; 375: 1–20
37. Kim HG, Koh GV: Lipopolysaccharide activates matrix metalloproteinase-2 in endothelial cells through an NF-kappaB-dependent pathway. Biochem Biophys Res Commun, 2000; 269(2): 401–5
38. Joyce D, Albanese C, Steer J et al: NF-kappaB and cell-cycle regulation: The cyclin connection. Cytokine Growth Factor Rev, 2001; 12(1): 73–90
39. Lee NK, Hwang K, Young S: TNF-related weak inducer of apoptosis receptor, a TNF receptor superfamily member, activates NF-kB through TNF receptor-associated factors. Biochem Biophys Res Commun, 2003; 305: 789–96
40. Brown M, Cohen J, Arun P et al: NF-kB in carcinoma therapy and prevention. Expert Opin Ther Targets, 2009; 12(9): 1109–22
41. Sovak MA, Bellas RE, Kim DW et al: Aberrant nuclear factor-xB/Rel expression and the pathogenesis of breast cancer. J Clin Invest, 1997; 100(12): 2952–60
42. Budunova IV, Perez P, Vaden VR et al: Increased expression of p50-NF-kB and constitutive activation of NF-xB transcription factors during mouse skin carcinogenesis. Oncogene, 1999; 18: 7423–31
43. Mayo MW, Baldwin AS: The transcription factor NF-xB, control of oncogenesis and cancer-therapy resistance. Biochim Biophys Acta, 2000; 1470(2): 55–62
44. Enaida H, Ito T, Oshima Y et al: Effect of growth factors on expression of integrin subtypes in microvascular endothelial cells isolated from bovine retinas. Fukushima J Med Sci, 1998; 44(1): 43–52
45. Li R, Maminishkis A, Zahn G et al: Integrin alpha5beta1 mediates attachment, migration, and proliferation in human retinal pigment epithelium: Relevance for proliferative retinal disease. Invest Ophthalmol Vis Sci, 2009; 50(12): 5988–96
46. Wilson SH, Ljubimov AV, Morla AO et al: Fibronectin fragments promote human retinal endothelial cell adhesion and proliferation and ERK activation through alpha5beta1 integrin and PI 3-kinase. Invest Ophthalmol Vis Sci, 2003; 44(4): 1704–15
47. Campbell S, Otis M, Cote M et al: Connection between integrins and cell activation in rat adrenal glomerulosa cells: A role for Arg-Gly-Asp peptide in the activation of the p42/p44(mapk) pathway and intracellular calcium. Endocrinology, 2003; 144(4): 1486–95